Compare Stocks: IFRX, GLUE, MNKD, and IMTX

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
GLUE Monte Rosa Therapeutics	$14.07 -1.7%	$18.05	$4.80 ▼ $25.77	$1.20B	1.5	995,057 shs	1.17 million shs
IFRX InflaRx	$2.09 +2.0%	$2.00	$0.80 ▼ $2.95	$308M	2.52	842,776 shs	334,148 shs
IMTX Immatics	$8.79 +0.5%	$9.34	$5.67 ▼ $12.41	$1.20B	1.33	651,536 shs	527,248 shs
MNKD MannKind	$3.75 -1.1%	$4.01	$2.23 ▼ $6.51	$1.21B	1.1	3.04 million shs	2.47 million shs

10 Best Stocks to Own - Fall 2026

Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Fall 2026, despite the economic uncertainty rattling markets right now. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
GLUE Monte Rosa Therapeutics	0.00%	+1.66%	-11.17%	-22.86%	+193.13%
IFRX InflaRx	0.00%	-5.86%	+3.98%	+30.63%	+32.28%
IMTX Immatics	0.00%	-8.05%	-8.34%	-6.29%	+51.29%
MNKD MannKind	0.00%	-7.64%	+0.54%	+2.46%	-32.68%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
GLUE Monte Rosa Therapeutics	$14.07 -1.7%	$18.05	$4.80 ▼ $25.77	$1.20B	1.5	995,057 shs	1.17 million shs
IFRX InflaRx	$2.09 +2.0%	$2.00	$0.80 ▼ $2.95	$308M	2.52	842,776 shs	334,148 shs
IMTX Immatics	$8.79 +0.5%	$9.34	$5.67 ▼ $12.41	$1.20B	1.33	651,536 shs	527,248 shs
MNKD MannKind	$3.75 -1.1%	$4.01	$2.23 ▼ $6.51	$1.21B	1.1	3.04 million shs	2.47 million shs

10 Best Stocks to Own - Fall 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
GLUE Monte Rosa Therapeutics	0.00%	+1.66%	-11.17%	-22.86%	+193.13%
IFRX InflaRx	0.00%	-5.86%	+3.98%	+30.63%	+32.28%
IMTX Immatics	0.00%	-8.05%	-8.34%	-6.29%	+51.29%
MNKD MannKind	0.00%	-7.64%	+0.54%	+2.46%	-32.68%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
GLUE Monte Rosa Therapeutics	2.78	Moderate Buy	$28.50	102.56% Upside
IFRX InflaRx	2.63	Moderate Buy	$7.33	250.88% Upside
IMTX Immatics	2.63	Moderate Buy	$20.60	134.36% Upside
MNKD MannKind	2.50	Moderate Buy	$8.34	122.50% Upside

Current Analyst Ratings Breakdown

Latest IFRX, GLUE, MNKD, and IMTX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/11/2026	MNKD MannKind	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight	$8.00
9/9/2026	GLUE Monte Rosa Therapeutics	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform	$27.00
9/3/2026	MNKD MannKind	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold ➝ Strong Sell
8/25/2026	IMTX Immatics	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$17.00
8/25/2026	GLUE Monte Rosa Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$28.00
8/25/2026	IFRX InflaRx	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
8/24/2026	GLUE Monte Rosa Therapeutics	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy
8/11/2026	GLUE Monte Rosa Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D+) ➝ Sell (D)
8/7/2026	GLUE Monte Rosa Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$35.00 ➝ $28.00
8/7/2026	GLUE Monte Rosa Therapeutics	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Overweight	$31.00 ➝ $27.00
8/7/2026	GLUE Monte Rosa Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Overweight	$29.00 ➝ $27.00

(Data available from 9/12/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
GLUE Monte Rosa Therapeutics	$123.67M	9.71	N/A	N/A	$3.58 per share	3.93
IFRX InflaRx	$30K	10,266.78	N/A	N/A	$0.65 per share	3.22
IMTX Immatics	$54.60M	22.01	N/A	N/A	$4.09 per share	2.15
MNKD MannKind	$348.97M	3.46	$0.06 per share	60.60	($0.17) per share	-22.06

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
GLUE Monte Rosa Therapeutics	-$38.63M	-$1.76	N/A	N/A	N/A	-560.85%	-43.31%	-27.59%	11/5/2026 (Estimated)
IFRX InflaRx	-$51.63M	-$0.58	N/A	N/A	N/A	N/A	-53.56%	-43.02%	11/9/2026 (Estimated)
IMTX Immatics	-$222.26M	-$1.86	N/A	N/A	N/A	-495.71%	-47.41%	-39.45%	11/17/2026 (Estimated)
MNKD MannKind	$5.86M	-$0.13	N/A	N/A	N/A	-11.08%	-11.21%	-6.31%	11/4/2026 (Estimated)

Latest IFRX, GLUE, MNKD, and IMTX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/18/2026	Q2 2026	IMTX Immatics	-$0.4748	-$0.53	-$0.0552	-$0.52	$12.42 million	$10.44 million
8/7/2026	Q2 2026	IFRX InflaRx	-$0.0666	-$0.11	-$0.0434	-$0.10	$0.01 million	N/A
8/6/2026	Q2 2026	GLUE Monte Rosa Therapeutics	-$0.3805	-$0.43	-$0.0495	-$0.43	$12.91 million	$8.97 million
8/5/2026	Q2 2026	MNKD MannKind	-$0.0075	-$0.01	-$0.0025	-$0.06	$108.08 million	$109.37 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
GLUE Monte Rosa Therapeutics	N/A	N/A	N/A	N/A	N/A
IFRX InflaRx	N/A	N/A	N/A	N/A	N/A
IMTX Immatics	N/A	N/A	N/A	N/A	N/A
MNKD MannKind	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
GLUE Monte Rosa Therapeutics	N/A	10.58	10.58
IFRX InflaRx	N/A	8.22	8.22
IMTX Immatics	N/A	7.54	7.54
MNKD MannKind	N/A	1.72	1.41

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
GLUE Monte Rosa Therapeutics	79.96%
IFRX InflaRx	42.39%
IMTX Immatics	64.41%
MNKD MannKind	49.55%

Insider Ownership

Company	Insider Ownership
GLUE Monte Rosa Therapeutics	6.40%
IFRX InflaRx	16.30%
IMTX Immatics	3.30%
MNKD MannKind	2.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
GLUE Monte Rosa Therapeutics	90	85.31 million	79.85 million	Optionable
IFRX InflaRx	60	147.37 million	123.35 million	Optionable
IMTX Immatics	260	136.69 million	132.18 million	Optionable
MNKD MannKind	400	321.54 million	313.18 million	Optionable

IFRX, GLUE, MNKD, and IMTX Headlines

Recent News About These Companies

Cantor Fitzgerald Keeps Their Buy Rating on MannKind (MNKD)

4 hours ago | theglobeandmail.com

Analysts Offer Insights on Healthcare Companies: Xeris Pharmaceuticals (XERS) and MannKind (MNKD)

September 11 at 5:56 PM | theglobeandmail.com

MannKind's (MNKD) Overweight Rating Reiterated at Cantor Fitzgerald

September 11 at 8:05 AM | marketbeat.com

MannKind inks obesity deal with Rose Pharma

September 9, 2026 | thepharmaletter.comT

MannKind, Rose Pharma Sign Deal to Develop Weight-Management Drug

September 9, 2026 | finance.yahoo.com

Breathing In GLP-1: MannKind Partners With Rose Pharma for Inhaled Weight Management Molecule

September 9, 2026 | benzinga.com

MannKind Expands Into Weight Loss With Rose Pharma Deal – Here’s What Investors Are Watching

September 9, 2026 | finance.yahoo.com

MannKind and Rose Pharma Enter Worldwide Collaboration to Develop Inhaled ROSE-010 Technosphere for Weight Management

September 9, 2026 | quiverquant.comQ

MannKind and Rose Pharma Inc Enter Licensing and Collaboration Agreement to Develop an Inhaled Rapid-Acting, Short-Duration GLP-1 for Weight Management

September 9, 2026 | globenewswire.com

Frazier Life Sciences Management L.P. Has $28.12 Million Holdings in MannKind Corporation $MNKD

September 7, 2026 | marketbeat.com

Bank of New York Mellon Corp Buys New Stake in MannKind Corporation $MNKD

September 6, 2026 | marketbeat.com

MannKind (NASDAQ:MNKD) Rating Lowered to "Strong Sell" at Zacks Research

September 5, 2026 | marketbeat.com

Wellington Management Group LLP Purchases 4,561,628 Shares of MannKind Corporation $MNKD

September 5, 2026 | marketbeat.com

Wells Fargo Remains a Buy on MannKind (MNKD)

September 3, 2026 | theglobeandmail.com

Braidwell LP Makes New Investment in MannKind Corporation $MNKD

September 3, 2026 | marketbeat.com

MannKind to Present at Upcoming Investor Conferences

September 2, 2026 | globenewswire.com

MannKind (NASDAQ:MNKD) Stock Crosses Above Two Hundred Day Moving Average - Here's What Happened

September 2, 2026 | marketbeat.com

FDA Accepts United Therapeutics' NDA Filing for Ralinepag in PAH

August 28, 2026 | zacks.com

MannKind Corporation $MNKD Shares Bought by Bank of America Corp DE

August 25, 2026 | marketbeat.com

MannKind Corporation (NASDAQ:MNKD) Receives Average Recommendation of "Moderate Buy" from Analysts

August 23, 2026 | marketbeat.com

MannKind (NASDAQ:MNKD) Stock Price Crosses Above 200-Day Moving Average - Time to Sell?

August 22, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

IFRX, GLUE, MNKD, and IMTX Company Descriptions

Monte Rosa Therapeutics NASDAQ:GLUE

$14.07 -0.25 (-1.75%)

Closing price 09/11/2026 04:00 PM Eastern

Extended Trading

$14.08 +0.00 (+0.04%)

As of 09/11/2026 07:39 PM Eastern

Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops MRT-2359, an orally bioavailable molecular glue degrader targeting the translation termination factor protein GSPT1 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of systemic and central nervous system autoimmune diseases; and MRT-8102 for the treatment of IL-1?/NLRP3 driven inflammatory diseases. It also develops CDK2 to treat ovarian, uterine, and breast cancers. The company was incorporated in 2019 and is headquartered in Boston, Massachusetts.

InflaRx NASDAQ:IFRX

$2.09 +0.04 (+1.95%)

Closing price 09/11/2026 04:00 PM Eastern

Extended Trading

$2.08 0.00 (-0.24%)

As of 09/11/2026 07:30 PM Eastern

InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage. The company develops INF904, an oral, small molecule drug candidate for the chronic inflammatory and autoimmune diseases; IFX002 that is in pre-clinical development stage for the treatment of chronic inflammation and autoimmune diseases; and Gohibic (vilobelimab) for the treatment of COVID-19 and broader ARDS. It has co-development agreement with Beijing Defengrei Biotechnology Co. Ltd.; and clinical trial collaboration and supply agreement with Merck & Co. Inc. The company was formerly known as Fireman B.V. and changed its name to InflaRx N.V. in 2017. InflaRx N.V. was founded in 2007 and is headquartered in Jena, Germany.

Immatics NASDAQ:IMTX

$8.79 +0.04 (+0.46%)

Closing price 09/11/2026 04:00 PM Eastern

Extended Trading

$8.80 +0.01 (+0.11%)

As of 09/11/2026 07:30 PM Eastern

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its products pipeline includes IMA203 that targets solid tumors, which is in Phase 1b clinical trial; IMA203CD8, a cell therapy product that is in Phase 1b clinical trial; IMA204 that targets tumor stroma, which is in preclinical stage; and IMA30x, an allogenic cellular therapy product candidate, which is in preclinical stage. The company also develops TCR Bispecifics products, including IMA401 and IMA402, which is in Phase 1a clinical trial. The company has a strategic collaboration agreement with MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies; Celgene Corporation to develop novel adoptive cell therapies targeting multiple cancers; and Genmab A/S to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications. Immatics N.V. is headquartered in Tübingen, Germany.

MannKind NASDAQ:MNKD

$3.75 -0.04 (-1.06%)

Closing price 09/11/2026 04:00 PM Eastern

Extended Trading

$3.77 +0.02 (+0.43%)

As of 09/11/2026 07:59 PM Eastern

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults. The company's product pipeline also includes Tyvaso DPI (Treprostinil), an inhalation powder for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; MNKD-101, a nebulized formulation of clofazimine, for the treatment of severe chronic and recurrent pulmonary infections, including nontuberculous mycobacterial lung disease; MNKD-201, a dry-powder formulation of nintedanib, for the treatment of idiopathic pulmonary fibrosis (IPF). In addition, it has collaboration and license agreement with United Therapeutics Corporation for development, regulatory, and commercial activities of Tyvaso DPI; co-promotion agreement with Vertice Pharma to promote Thyquidity; and collaboration agreement with Thirona to evaluate the therapeutic for the treatment of pulmonary fibrosis. Further, the company has supply and distribution agreement with Biomm S.A. for the commercialization of Afrezza in Brazil; and license and distribution agreement with Cipla Ltd. for the marketing and distribution of Afrezza in India. MannKind Corporation was incorporated in 1991 and is headquartered in Danbury, Connecticut.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest IFRX, GLUE, MNKD, and IMTX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest IFRX, GLUE, MNKD, and IMTX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

IFRX, GLUE, MNKD, and IMTX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

IFRX, GLUE, MNKD, and IMTX Company Descriptions

Monte Rosa Therapeutics NASDAQ:GLUE

InflaRx NASDAQ:IFRX

Immatics NASDAQ:IMTX

MannKind NASDAQ:MNKD

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest IFRX, GLUE, MNKD, and IMTX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest IFRX, GLUE, MNKD, and IMTX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

IFRX, GLUE, MNKD, and IMTX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

IFRX, GLUE, MNKD, and IMTX Company Descriptions

Monte Rosa Therapeutics NASDAQ:GLUE

InflaRx NASDAQ:IFRX

Immatics NASDAQ:IMTX

MannKind NASDAQ:MNKD

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools